New drug aims to unblock Crohn's-Damaged intestines
NCT ID NCT06997965
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether mirikizumab, an injected drug that blocks IL-23, can reduce inflammatory strictures (narrowed areas) in the small bowel caused by Crohn's disease. About 60 adults with at least one stricture will receive the drug and be monitored with MRI and symptom scores. The goal is to see if the strictures shrink and symptoms improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mirikizumab (Omvoh)
What this could lead to
If successful, this could show that mirikizumab helps shrink inflammatory strictures in Crohn's disease, potentially reducing the need for surgery.
What could go wrong
This is a small, early-phase, open-label study with no placebo group, so results may be less reliable. It is not designed to prove a cure, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Digestive & Liver Center of Florida
RECRUITINGOrlando, Florida, 32825, United States
Contact Email: •••••@•••••
-
Velocity Clinical- Salt Lake City
ACTIVE_NOT_RECRUITINGSalt Lake City, Utah, 84088, United States